DigestRedComo funciona
Red
/
Empresas
Me
No verificado

Merck Sharp & Dohme

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

11 Comunicados de prensa

Ver todos los comunicados de prensa
20/04/2026
Industria
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
17/03/2026
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Finanzas
Eventos
Industria
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
07/01/2026
Mercado de valores
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Merck to Complete Acquisition of Cidara Therapeutics
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
01/12/2025
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Finanzas
Industria
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
26/11/2025
Web y redes sociales
Eventos
Finanzas
Salud
Sanidad
Ciencia
Farmacéutica
Biotecnología
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
03/11/2025
Responsabilidad Social Corporativa
Voluntariado/Solidaridad/ONGs
Asociaciones/Profesionales
Cardiología
Biotecnología
Farmacéutica
Salud
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
09/10/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Industria
Eventos
Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
06/10/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
30/09/2025
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Medicina - Varios
Industria
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0
10/07/2025
Ciencia
VIH, SIDA y enfermedades autoinmunes
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Industria
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
Fuente
Merck Sharp & Dohme
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0